Release
📈 Stocks
Eli Lilly Shares Rally as EloraTZP Data Shows 23.3% Weight Loss in Phase 2b
(9 hours ago)
Eli Lilly's EloraTZP trial results show a 23.3% average weight loss, signaling a potential new benchmark in the company's obesity and type…